Herbalife (HLF) vs Nu Skin Enterprises (NUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Herbalife (HLF) has outperformed Nu Skin Enterprises (NUS) over the past year, gaining 42.8% versus a loss of 57.6%. Over five years, HLF leads with a -70.9% price change compared with -88.4% for NUS. Herbalife is the larger company by market cap ($1.33 billion vs $232.2 million), about 5.7 times the size.
On valuation, Nu Skin Enterprises trades at a lower forward P/E (4.1x vs 4.2x for Herbalife). Nu Skin Enterprises pays a dividend yielding 5.03%, while Herbalife does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HLF | NUS |
|---|---|---|
| Share price | $12.82 | $4.77 |
| Market cap | $1.33B | $232.19M |
| 1-day change | +1.34% | -0.63% |
| YTD return | -1.86% | -50.42% |
| 1-year return | +42.78% | -57.64% |
| 5-year return | -70.91% | -88.38% |
| P/E ratio (TTM) | 8.17 | — |
| Forward P/E | 4.16 | 4.11 |
| EPS (TTM) | $1.57 | $-4.51 |
| Dividend yield | 0.00% | 5.03% |
| Annual dividend | $0.00 | $0.24 |
| 52-week high | $20.40 | $11.67 |
| 52-week low | $7.56 | $4.45 |
| Distance from 52-week high | -37.16% | -59.13% |
| Analyst consensus | none | none |
| Avg. price target upside | +32.61% | +167.71% |
| Average volume | 1.54M | 557.63K |
| Shares outstanding | 103.67M | 48.68M |
| Employees | 8,500 | 2,800 |
| Sector | Health Care | Health Care |
| Industry | Other Pharmaceuticals | Other Pharmaceuticals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Herbalife is about 5.7 times larger than Nu Skin Enterprises by market value ($1.33B vs $232.19M).
- HLF has outperformed NUS by 100.4 percentage points over the past year.
- Nu Skin Enterprises offers a meaningfully higher dividend yield (5.03% vs 0.00%).
About Herbalife
HLF stock →Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers weight management products, including meal replacement, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism boosting teas; targeted nutrition products comprising functional beverages and dietary and nutritional supplements containing herbs, vitamins, minerals and other natural ingredients; energy, sports, and fitness products; and facial skin care, body care, and hair care products.
Health Care · Other Pharmaceuticals · 8,500 employees
About Nu Skin Enterprises
NUS stock →Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands.
Health Care · Other Pharmaceuticals · 2,800 employees
HLF vs NUS FAQ
Which is bigger, Herbalife or Nu Skin Enterprises?
Herbalife (HLF) is larger, with a market capitalization of $1.33B compared with $232.19M for Nu Skin Enterprises (NUS).
Which stock has performed better over the past year, HLF or NUS?
HLF returned +42.78% over the past 12 months, compared with -57.64% for NUS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Herbalife or Nu Skin Enterprises?
Nu Skin Enterprises pays a dividend yielding 5.03%, while Herbalife does not currently pay a regular dividend.
Are Herbalife and Nu Skin Enterprises in the same industry?
Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.